Antigenic targets in clear cell renal cell carcinoma

被引：2

作者：

Schindler, Nicholas R. ^{[1
,2
]}

Braun, David A. ^{[1
,2
]}

机构：

[1] Yale Sch Med, Dept Internal Med, Sect Med Oncol, New Haven, CT USA

[2] Yale Sch Med, Yale Canc Ctr, Ctr Mol & Cellular Oncol, New Haven, CT USA

来源：

KIDNEY CANCER | 2023年 / 7卷 / 01期

关键词：

Renal cell carcinoma; tumor antigen; neoantigen; cancer vaccine; T cell receptor; chimeric antigen receptor T cell; TUMOR-INFILTRATING LYMPHOCYTES; CYTOLYTIC T-LYMPHOCYTES; SELECTIVE EXPRESSION; 1ST-LINE THERAPY; CANCER VACCINE; MELANOMA; NEOANTIGENS; SUNITINIB; RESPONSES; IMA901;

D O I：

10.3233/KCA-230006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibitors (ICIs) have transformed the management of advanced renal cell carcinoma (RCC), but most patients still do not receive a long-term benefit from these therapies, and many experience off-target, immune-related adverse effects. RCC is also different from many other ICI-responsive tumors, as it has only a modest mutation burden, and total neoantigen load does not correlate with ICI response. In order to improve the efficacy and safety of immunotherapies for RCC, it is therefore critical to identify the antigens that are targeted in effective anti-tumor immunity. In this review, we describe the potential classes of target antigens, and provide examples of previous and ongoing efforts to investigate and target antigens in RCC, with a focus on clear cell histology. Ultimately, we believe that a concerted antigen discovery effort in RCC will enable an improved understanding of response and resistance to current therapies, and lay a foundation for the future development of "precision" antigen-directed immunotherapies.

引用

页码：81 / 91

页数：11

共 82 条

[21] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma [J].

Choueiri, T. K. ;

Powles, T. ;

Burotto, M. ;

Escudier, B. ;

Bourlon, M. T. ;

Zurawski, B. ;

Juarez, V. M. Oyervides ;

Hsieh, J. J. ;

Basso, U. ;

Shah, A. Y. ;

Suarez, C. ;

Hamzaj, A. ;

Goh, J. C. ;

Barrios, C. ;

Richardet, M. ;

Porta, C. ;

Kowalyszyn, R. ;

Feregrino, J. P. ;

Zolnierek, J. ;

Pook, D. ;

Kessler, E. R. ;

Tomita, Y. ;

Mizuno, R. ;

Bedke, J. ;

Zhang, J. ;

Maurer, M. A. ;

Simsek, B. ;

Ejzykowicz, F. ;

Schwab, G. M. ;

Apolo, A. B. ;

Motzer, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) :829-841

[22] Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management [J].

Courcier, Jean ;

de la Taille, Alexandre ;

Nourieh, Maya ;

Leguerney, Ingrid ;

Lassau, Nathalie ;

Ingels, Alexandre .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (19) :1-15

[23] Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy [J].

Cristescu, Razvan ;

Mogg, Robin ;

Ayers, Mark ;

Albright, Andrew ;

Murphy, Erin ;

Yearley, Jennifer ;

Sher, Xinwei ;

Liu, Xiao Qiao ;

Lu, Hongchao ;

Nebozhyn, Michael ;

Zhang, Chunsheng ;

Lunceford, Jared ;

Joe, Andrew ;

Cheng, Jonathan ;

Webber, Andrea L. ;

Ibrahim, Nageatte ;

Plimack, Elizabeth R. ;

Ott, Patrick A. ;

Seiwert, Tanguy ;

Ribas, Antoni ;

McClanahan, Terrill K. ;

Tomassini, Joanne E. ;

Loboda, Andrey ;

Kaufman, David .

SCIENCE, 2018, 362 (6411) :197-+

[24] Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study [J].

Demasure, Sofie ;

Spriet, Isabel ;

Debruyne, Philip R. ;

Laenen, Annouschka ;

Wynendaele, Wim ;

Baldewijns, Marcella ;

Dumez, Herlinde ;

Clement, Paul M. ;

Wildiers, Hans ;

Schoffski, Patrick ;

Roussel, Eduard ;

Kinget, Lisa ;

Albersen, Maarten ;

Beuselinck, Benoit .

ACTA ONCOLOGICA, 2022, 61 (01) :22-29

[25] Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T-Cells, Which Dampen CD8+ T-cell Antitumor Reactivity [J].

Donia, Marco ;

Andersen, Rikke ;

Kjeldsen, Julie W. ;

Fagone, Paolo ;

Munir, Shamaila ;

Nicoletti, Ferdinando ;

Andersen, Mads Hald ;

Straten, Per Thor ;

Svane, Inge Marie .

CANCER RESEARCH, 2015, 75 (18) :3747-3759

[26] Role and Mechanisms of RAGE-Ligand Complexes and RAGE-Inhibitors in Cancer Progression [J].

El-Far, Ali H. ;

Sroga, Grazyna ;

Al Jaouni, Soad K. ;

Mousa, Shaker A. .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (10)

[27] Uncovering the Tumor Antigen Landscape: What to Know about the Discovery Process [J].

Feola, Sara ;

Chiaro, Jacopo ;

Martins, Beatriz ;

Cerullo, Vincenzo .

CANCERS, 2020, 12 (06) :1-28

[28] Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma [J].

Figlin, Robert A. ;

Tannir, Nizar M. ;

Uzzo, Robert G. ;

Tykodi, Scott S. ;

Chen, David Y. T. ;

Master, Viraj ;

Kapoor, Anil ;

Vaena, Daniel ;

Lowrance, William ;

Bratslaysky, Gennady ;

DeBenedette, Mark ;

Gamble, Alicia ;

Plachco, Ana ;

Norris, Marcus S. ;

Horvatinovich, Joe ;

Tcherepanova, Irina Y. ;

Nicolette, Charles A. ;

Wood, Christopher G. .

CLINICAL CANCER RESEARCH, 2020, 26 (10) :2327-2336

[29] The CD70-CD27 axis in oncology: the new kids on the block [J].

Flieswasser, Tal ;

Van den Eynde, Astrid ;

Van Audenaerde, Jonas ;

De Waele, Jorrit ;

Lardon, Filip ;

Riether, Carsten ;

de Haard, Hans ;

Smits, Evelien ;

Pauwels, Patrick ;

Jacobs, Julie .

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2022, 41 (01)

[30] The biology of cancer testis antigens: Putative function, regulation and therapeutic potential [J].

Fratta, Elisabetta ;

Coral, Sandra ;

Covre, Alessia ;

Parisi, Giulia ;

Colizzi, Francesca ;

Danielli, Riccardo ;

Nicolay, Hugues Jean Marie ;

Sigalotti, Luca ;

Maio, Michele .

MOLECULAR ONCOLOGY, 2011, 5 (02) :164-182

← 1 2 3 4 5 6 7 8 9 →